Market Newsdesk

SAN DIEGO, Sept. 9, 2021 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the NuVasive Simplify^® Cervical Disc one-level U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) study data was recently published in the International Journal of Spine Surgery. The data was utilized in the device’s FDA pre-market application for one-level indication approval in September 2020.

The peer-reviewed study reiterates that the Simplify Cervical Disc has a significantly greater success rate at the 24-month follow up compared to anterior cervical discectomy and fusion (ACDF) when used in treatment for one-level cervical total disc replacement (cTDR).¹ Findings from this study include:

• Mean Neck Disability Index (NDI), a patient-reported measure for disability related to cervical spinal disorders, was significantly lower for patients who underwent a cTDR with the Simplify Cervical Disc compared to ACDF;
• Range of motion significantly increased for cTDR patients treated with the Simplify Cervical Disc at three months and was maintained throughout follow ups; and
• Facet joint degeneration assessment by MRI showed little change from pre- to post-operation in the cTDR patients. This is the first time 24-month follow up MRI scans were used in an IDE study for cTDR.² The Simplify Cervical Disc allows for enhanced visualization through MRI postoperatively compared to alternative devices, a key imaging modality in spine.

“This recent peer-reviewed publication validates the strong clinical data behind the Simplify Cervical Disc and why this is the most clinically effective technology in the cTDR procedure segment,” said Kyle Malone, vice president of Clinical, Medical, and Regulatory Affairs at NuVasive. “As we continue to pursue Simplify Cervical Disc clinical data, we are encouraged by these results to support our commitment to outcome-driven innovation in spine surgery that benefits surgeons, hospitals, and—most importantly—patients.”

The Simplify Cervical Disc is part of the NuVasive C360™ portfolio, which offers comprehensive, procedurally integrated solutions for the cervical spine across ACDF, posterior cervical fusion, and cTDR procedures. The device is designed with key performance functions that include a radiologic design, anatomic disc heights, and physiologic motion. Overall, the Simplify Cervical Disc demonstrates clinical superiority to ACDF³ and has the highest overall clinical success rate compared to any other approved cervical disc at both one- and two-levels.² It is one of three devices approved for use in two-level cTDR procedures.²

“I am excited to see this study published on the Simplify Cervical Disc’s one-level FDA trial,” said Richard Guyer, MD, orthopedic spine surgeon and co-founder of the Texas Back Institute in Plano, Texas. “Not only were the disc’s results excellent for the cTDR procedure compared to fusion, but it also breaks new ground in cervical technology by offering a combination of smaller, more anatomic disc heights, reproducing a spine’s natural motion, and being entirely MRI compatible unlike other cTDR implants.”

This data will also be presented by Dr. Guyer at the following industry conferences with recognition in the best paper section for each respective meeting:

• North American Spine Society 36^th Annual Meeting on Wednesday, September 29, 2021
• Cervical Spine Research Society 49^th Annual Meeting on Saturday, December 4, 2021

About NuVasive

NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The Company’s less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company’s comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With more than $1 billion in net sales, NuVasive has approximately 2,700 employees and operates in more than 50 countries serving surgeons, hospitals, and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements

NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products, the Company’s ability to adequately manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made. 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvasive-simplify-cervical-disc-data-published-in-international-journal-of-spine-surgery-301372068.html

SOURCE NuVasive, Inc.

PLANO, Texas, Sept. 9, 2021 /PRNewswire/ — Fresh off the sale of the record-setting 50-millionth Corolla, the best-selling car of all time welcomes a versatile new family member with the introduction of the 2022 Toyota Corolla Cross. Value-priced and packed with features not typically found in a small crossover, Corolla Cross hits the sweet spot with the engaging driving experience of a small car and the functionality of a larger crossover. The 2022 Toyota Corolla Cross, based on the ever-popular Corolla sedan, is coming to dealerships this October with a starting MSRP of $22,195 for the front-wheel drive base grade. And a bump up to all-wheel drive will be available for an extra $1,300.

The all-new 2022 Corolla Cross will be assembled in the U.S. at the new Mazda Toyota Manufacturing plant in Huntsville, Alabama – a brand new facility that will have the capacity to produce up to 150,000 Corolla Cross vehicles per year.

“For over 50 years, Corolla has been synonymous with dependability, fuel efficiency, safety and value,” said Lisa Materazzo, group vice president of Toyota Marketing.  “With the all-new Corolla Cross, we are building upon that foundation and offering even more versatility and creature comforts to make everything from a daily commute to a weekend escape more memorable.”

Available in front-wheel drive (FWD) and all-wheel drive (AWD), the compact SUV maximizes the inherent potential of the high-strength TNGA-C platform and a 169-horsepower 2.0-liter Dynamic Force Engine. This enables the Corolla Cross to achieve high-quality performance, a comfortable ride and outstanding spaciousness. What’s more, the surprising cargo capacity gives it the versatility to accommodate life’s adventures.

Well Appointed, Yet Powerful

Offered in three grades – L, LE and XLE – the versatile design of the Corolla Cross is spacious, modern, powerful and high quality. From an engineering perspective, it offers an approachable exterior as well as a higher line-of-sight thanks to the revised TNGA-C platform. Key design cues include a distinctive black grille flanked by LED lighting with black body accents – giving the entry SUV a confident appearance. And from the rear, the stylish design elements continue, with an integrated rear spoiler and LED lighting. Wheel options range from 17-inch steel on L to 18-inch alloy on XLE.

For exterior color options, the 2022 Corolla Cross is offered in:

• Wind Chill Pearl ($425 extra-color cost)
• Celestite
• Sonic Silver
• Jet Black
• Barcelona Red Metallic
• Cypress
• Blue Crush Metallic

Inside, Corolla Cross’ spacious interior offers many of the same desirable features as its sedan and hatchback siblings. The all-new model can be outfitted with a power moonroof, as well as either single- or dual-zone automatic climate control, with all grades featuring standard heating and air conditioning vents for rear seat passengers.

For interior color options, the 2022 Corolla Cross is offered in:

• L: Fabric-trimmed seats in Light Gray
• LE: Fabric-trimmed seats in Light Gray or Black
• XLE: SofTex®-trimmed seats in Macadamia/Mocha or Black

A 10-way power-adjustable driver’s seat with lumbar and heated front seats, standard on XLE, put the driver in a comfortable and commanding position.

In back, storage space can be maxed out thanks to the 60/40-split folding rear seats that come standard on all grades, while XLE models also include a center armrest with two additional cupholders. To make access to the roomy cargo area even more convenient, the Corolla Cross has an available power liftgate with height adjustability.

Available accessories, including a roof rack with crossbars, an activity mount for carrying items such as bicycles, a tow hitch and all-weather floormats keep you equipped for any adventure.

Small But Mighty

The Corolla Cross is equipped with the mighty Dynamic Force four cylinder, 2.0-liter DOHC 16-valve with Dual Variable Valve Timing with intelligence (VVT-i) engine. That means a punchy 169 horsepower engine paired with CVT with a physical first gear provides a truly engaging driving experience, all while delivering exceptional efficiency.

Corolla Cross’ suspension also plays a role here, as it’s fully independent for all-wheel-drive models, while front-wheel-drive vehicles feature a brand-new torsion beam system in the rear.

Additionally, every Corolla Cross is capable of towing up to 1,500 lbs. (enough to pull a trailer with a personal watercraft for a day of fun on the lake).

For those who choose AWD, Toyota’s clever Dynamic Torque Control system directs up to 50% of power to the rear wheels when it’s needed – and disengages completely when it’s not. This feature helps Corolla Cross maintain great fuel economy – another strong suit for this powertrain – with an estimated 32 combined MPG for the FWD model and an estimated 30 combined MPG for the AWD model.

Connectivity for the Long Drive

However, passengers choose to listen to music or connect with their worlds, the 2022 Corolla Cross is ready with the latest multimedia systems. A 7-inch multimedia touchscreen comes on the L grade, while LE and XLE feature an 8-inch touchscreen.

The vast range of in-car entertainment and connected functionalities, including standard compatibility for Apple CarPlay and Android Auto, will be sure to keep passengers engaged. Mobile devices will stay topped off through wireless charging (standard on LE and XLE), or through the conveniently located USB media port. LE and XLE grades offer two USB charging ports for rear seat passengers, welcoming all devices along for the drive!

The available Audio Plus multimedia with Remote Connect and a nine-speaker JBL® sound system is the perfect complement to a road trip playlist. And when it’s time to turn on the tunes, Amazon Alexa connectivity keeps Amazon’s digital assistant just a question away. Other connected features include a standard three-month SiriusXM Platinum subscription to more than 300 channels accessible throughout the country.

XLE owners can get key info at a glance, courtesy of an available 7-inch Multi-Information Display with various vehicle and systems info to choose from.

Exceptional Toyota Value, Naturally

Toyota’s typical outstanding value is clearly evident throughout the lineup, from the entry-level Corolla Cross L grade all the way up to the top-of-the-line XLE grade. All trims are offered in both FWD and AWD.

Standard features include the following.

L Grade:

• 7″ Multimedia Display
• 4.2″ MID
• Apple CarPlay®, Android Auto™ and Amazon Alexa
• SiriusXM® trial
• Rear HVAC Vents
• TSS 2.0
• Remote Keyless Entry
• Two USB ports
• LED headlights and taillights
• 17″ Steel wheels with silver wheel covers

LE Grade – L features plus:

• 8″ Multimedia display
• Qi-wireless charging
• Blind Spot Monitor with Rear Cross-Traffic Alert
• 17″ alloy wheels
• Roof rails
• Smart Key with Push Button Start
• Leather wrapped steering wheel
• Auto climate control
• Three USB ports
• Color-keyed heated power outside mirrors with turn signals

XLE Grade – LE features plus:

• 18″ alloy wheels
• 7″ MID
• SofTex®-trimmed seats
• 10-way power driver seat with lumbar
• Heated front seats
• LED DRLs and fog lights
• Rear Cross-Traffic Brake
• Front and Rear Parking Assist with Automatic Braking
• Dual zone climate control
• Rear folding armrest with two cup holders
• Leather shift knob
• Tonneau cover

Options:

• LE :
• Audio Plus with JBL® 9-speaker system
• Moonroof package
• Moonroof
• Tonneau cover
• XLE:
• Audio Plus with JBL® 9-speaker system
• Convenience Package
• Moonroof
• Power rear liftgate
• Adaptive Front Lighting System with auto-leveling

Safety

True to Toyota form, modern safety is key for Corolla Cross. That’s why all grades come standard with both the Toyota Safety Sense suite of advanced active safety systems, as well as Toyota’s signature STAR Safety System. Blind Spot Monitor and Rear Cross-Traffic Alert come standard on LE and XLE, while Front and Rear Parking Assist with Automatic Braking is standard on XLE. All grades come standard with nine airbags throughout the cabin to help protect occupants.

Toyota Safety Sense 2.0 is a comprehensive active safety system that includes:

• Pre-Collision System with Pedestrian and Cyclist Detection (PCS with PD)
• Lane Departure Alert (LDA) with Steering Assist
• Lane Tracing Assist (LTA)
• Road Sign Assist (RSA)
• Full-Speed Range Dynamic Radar Cruise Control (DRCC)
• Automatic High Beams (AHB)

The Toyota STAR Safety System includes:

• Enhanced Vehicle Stability Control (Enhanced VSC)
• Traction Control (TRAC)
• Anti-lock Brake System (ABS)
• Electronic Brake-force Distribution (EBD)
• Brake Assist (BA)
• Smart Stop Technology (SST)

2022 Corolla Cross Pricing*

*MSRP does not include delivery, processing and handling (DPH) of $1,215.

Limited Warranty

Toyota’s 36-month/36,000 mile basic new-vehicle warranty applies to all components other than normal wear and maintenance items. Additional 60-month warranties cover the powertrain for 60,000 miles and against perforation from corrosion for 60 months with no mileage limitation.

The 2022 Corolla Cross also comes standard with ToyotaCare, a complimentary plan covering normal factory-scheduled maintenance, for two years or 25,000 miles, whichever comes first, and two years of Roadside Assistance, regardless of mileage.

About Toyota

Toyota (NYSE:TM) has been a part of the cultural fabric in North America for more than 60 years, and is committed to advancing sustainable, next-generation mobility through our Toyota and Lexus brands plus our 1,800 dealerships.

Toyota has created a tremendous value chain and directly employs more than 47,000 in North America. The company has contributed world-class design, engineering, and assembly of more than 40 million cars and trucks at our 14 manufacturing plants, 15 including our joint venture in Alabama that begins production in 2021.

Through its Start Your Impossible campaign, Toyota highlights the way it partners with community, civic, academic and governmental organizations to address our society’s most pressing mobility challenges. We believe that when people are free to move, anything is possible. For more information about Toyota, visit

www.toyotanewsroom.com

.

Media Contacts
Nicky Hamila
469-292-3596
[email protected]

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/toyota-corolla-cross-all-new-body-style-adds-utility-fun-301372175.html

SOURCE Toyota

TOLEDO, Ohio, Sept. 9, 2021 /PRNewswire/ — In conjunction with upcoming investor conferences, Welltower® Inc. (NYSE: WELL) has issued the following business update which can be found at:

https://welltower.com/september-business-update

About Welltower

Welltower® Inc. (NYSE: WELL), an S&P 500 company headquartered in Toledo, Ohio, is driving the transformation of health care infrastructure. The Company invests with leading seniors housing operators, post-acute providers, and health systems to fund the real estate infrastructure needed to scale innovative care delivery models and improve people’s wellness and overall health care experience. Welltower, a real estate investment trust (“REIT”), owns interests in properties concentrated in major, high-growth markets in the United States, Canada, and the United Kingdom, consisting of seniors housing, post-acute communities and outpatient medical properties. More information is available at www.welltower.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/welltower-issues-business-update-301372187.html

SOURCE Welltower Inc.

REHOVOT, Israel, Sept. 9, 2021 /PRNewswire/ — CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that Mr. Yehiel Tal, Chief Executive Officer of CollPlant, has been elected to the Board of Directors of the International Society for Biofabrication (ISBF) for a three-year term starting January 1^st 2022.

Mr. Tal was appointed to the Board of Directors of ISBF in recognition of his deep involvement, experience and understanding of the 3D bioprinting industry. The ISBF is a scientific and professional Society, which promotes advances in Biofabrication research, development, education, training, and medical and clinical applications. The ISBF’s core purpose is to foster scientific and technological innovation and excellence for the benefit of humanity.

“I am honored to be elected to the Board of Directors of the ISBF, and to work with others who are shaping and advancing the field of biofabrication which holds great promise in development of in vitro 3D models, tissue engineering and regenerative therapies” stated Mr. Tal.

“We are pleased to welcome Mr. Tal to ISBF’s Board of Directors,” stated Prof.  James J. Yoo, ISBF President, ”  Mr. Tal is a highly accomplished innovator in the field of 3D bioprinting and will bring a level of knowledge and passion that will greatly benefit our organization’s mission to foster scientific and technological advancement in the field of biofabrication that benefits humanity.”

About the International Society for Biofabrication

The International Society for Biofabrication (ISBF) is a scientific and professional Society, which promotes advances in Biofabrication research, development, education, training, and medical and clinical applications. ISBF represents the international Biofabrication community and operate as a non-profit organization. ISBF’s core purpose is to foster scientific and technological innovation and excellence for the benefit of humanity. ISBF promote the interaction between the different disciplines of the field of Biofabrication, as well as between basic research and applied practice; and cooperate with other scientific organizations and communities.

About CollPlant

CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company’s products are based on its recombinant human collagen produced with CollPlant’s proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.   

CollPlant recently entered a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. Later in 2021, CollPlant entered a strategic co-development agreement with 3D Systems for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant.

For more information, visit http://www.collplant.com.

Safe Harbor Statements

This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant’s objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant’s actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company’s history of significant losses, its ability to continue as a going concern, and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the impact of the COVID-19 pandemic; the Company’s expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based BioInk and products for medical aesthetics; the Company’s ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based BioInk and medical aesthetics products including but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company’s rhCollagen based products in 3D Bioprinting and medical aesthetics; the Company’s ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company’s ability to establish and maintain strategic partnerships and other corporate collaborations; the Company’s reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company’s ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; changes in the Company’s strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant is contained under the heading “Risk Factors” included in CollPlant’s most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant’s current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 

Contact at CollPlant:

Eran Rotem

Deputy CEO & Chief Financial Officer
Tel: + 972-73-2325600/631
Email: [email protected]

Photo – https://mma.prnewswire.com/media/1611908/Yehiel_Tal_CollPlant_CEO.jpg

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/collplant-ceo-yehiel-tal-elected-to-the-board-of-directors-of-the-international-society-for-biofabrication-isbf-301372210.html

SOURCE CollPlant

• 
  3.0m (ETW) Grading 3,319 gpt AgEq
• 
  3.6m (ETW) Grading 2,815 gpt AgEq
• 
  0.4m (ETW) Grading 7,249 gpt AgEq

TSX: SIL | NYSE American:SILV

VANCOUVER, BC, Sept. 9, 2021 /PRNewswire/ – SilverCrest Metals Inc. (“SilverCrest” or the “Company”) is pleased to announce that its 2021 planned infill drilling for the Babi Vista Vein (“Babi Vista”), Babi Vista Vein Splay (“Splay”), and Granaditas  Vein 1 Vein (“Granaditas”) is nearing completion, along with continuation of expansion drilling in the Babicanora Area of its Las Chispas Project (“Las Chispas” or the “Project”) located in Sonora, Mexico (see following Tables and attached Figures). The objective of this drilling program is to increase drill density in an area proximal to current and planned underground development. This drilling is targeting conversion of an estimated 15.4M oz AgEq grading 9.97 gpt Au and 707.9 gpt Ag, or 1,574 gpt AgEq (86.9:1 Au:Ag ratio, see note below tables) of Inferred Resources (as stated in the “2021 Feasibility Study”¹) to higher confidence Indicated Resources to support an updated Mineral Reserve and Life of Mine Plan (“LOM”) in 2022.

Highlights:

• Infill Drilling – During the first seven months of 2021, a total of 80,632 metres in 176 drill holes have been completed at Las Chispas. This includes a total of 52,035 metres in 141 infill drill holes in the Babi Vista, Splay, and Granaditas veins with approximately 20% of infill holes intersecting grades greater than 1,000 gpt AgEq (see attached Figures):
• Confirmation of Targeted Areas – The infill program increased estimated drill density to 25 to 35 metres (from 45 to 50 metres) over a strike length of 1.3 kilometres and successfully confirmed the grades and approximate footprint of Inferred Resources reported in the 2021 Feasibility Study.
• Delineation of High-Grade “Shoot 201” – Infill drilling confirmed a multi-kilogram per tonne (AgEq basis) zone now named “Shoot 201” in the Splay, which surrounds the previous high-grade results in hole BV20-201, 203 and 207 (see News Release November 16, 2020). This zone has now been better defined with 11 additional holes that have an average uncapped, undiluted grade of 30.04 gpt Au and 2,429.4 gpt Ag, or 5,040 gpt AgEq, over an estimated true width (“ETW”) of 1.4 metres, within a high-grade footprint of approximately 100 metres by 75 metres. Shoot 201, along with the balance of the Splay and Granaditas, are currently not in the reserves or LOM and will be considered for conversion in an updated study in 2022.
• Expansion Drilling – 16 expansion holes totalling 8,118 metres were completed in the renamed Babi Vista FW Zone (multiple veins) and the Babicanora Norte HW Vein (see attached Figures);
• Babi Vista FW Vein Becomes Babi Vista FW Zone – A total of 18 new intercepts having an ETW of 0.57 metres grading 5.54 gpt Au and 680.2 gpt Ag, or 1,162 gpt AgEq have expanded the Babi Vista FW Vein, which is now renamed the Babi Vista FW Zone to incorporate the presence of several new sub-parallel and semi-continuous veins between the Splay and Babicanora Norte veins.
• Babicanora Norte HW Vein – This vein has been expanded by approximately 300 metres along strike (see 2021 Feasibility Study). Ten new intercepts have an ETW of 0.40 metres grading 2.0 gpt Au and 260 gpt Ag, or 434 gpt AgEq.
• H2, 2021 Focus on Infill, Expansion and Exploration – With infill drilling complete on Babi Vista, Splay, and Granaditas, the Company is working to complete other infill drilling on Babicanora Norte NW while transitioning to expansion and new exploration drilling within the Babicanora Area.

N. Eric Fier, CPG, P.Eng, and CEO, remarked, “SilverCrest’s strategy for its infill drilling program is to efficiently use our capital to optimize the LOM through increasing confidence in high-grade Inferred Resource veins proximal to planned underground infrastructure. The infill program has confirmed the presence and continuity of multi-kilogram per tonne silver equivalent grades within the footprints that helped define the veins in the 2021 Feasibility Study. The program also confirmed discovery of Shoot 201, located in the Splay, which shows some of the highest precious metal grades at the project and is not yet considered in the Las Chispas Mineral Reserve. We remain focused on execution of the Las Chispas Project construction and underground mine development and will evaluate the potential opportunity for in-vein drifting in the Splay and Shoot 201 to complete further technical evaluation. With the infill program nearing completion, the drilling focus will shift towards expansion and grass roots exploration work on the over 30 veins on the Las Chispas property that remain undrilled or are not yet fully tested.”

The Company’s focus for the infill drill program to date was to target the 15.4 Moz AgEq Inferred Resources in the Babi Vista, Splay and Granaditas veins. At an average grade of greater than 1,500 gpt AgEq (uncapped, undiluted), these ounces have a grade more than 70% higher than the average grade of the 2021 Feasibility Study Mineral Reserve (94.7 Moz AgEq at an average grade of 879 gpt AgEq, capped and diluted).  The infill drilling prioritized drilling ounces near existing infrastructure which have the potential to further de-risk and improve the current mine plan. 

Infill drilling has shown that high-grade footprints (grading >150 gpt AgEq) for the infilled veins are similar to previous footprints presented in the 2021 Feasibility Study. As mentioned in a news release dated April 15, 2021, this combined footprint for Babi Vista, Splay, and Granaditas, including Mineral Resources and exploration high-grade intercepts, can be traced for an estimated 1.3 kilometres of strike length.

Infill drilling results show similar to improved grades for the Splay and Granaditas veins relative to the average 2021 Feasibility Study Inferred Resource silver equivalent grades:

• For the Splay, the 2021 Feasibility Study Inferred Resource contains 13.9 Moz AgEq at an average grade (capped, undiluted) of 13.00 gpt Au and 909.4 gpt Ag, or 2,039 gpt AgEq with an ETW of 1.27 metres. Comparatively, infill holes included in this release for this vein average (uncapped, undiluted) 15.38 gpt Au and 1,282.8 gpt Ag, or 2,619 gpt AgEq with ETW of 1.0 metres.
• For Granaditas, the 2021 Feasibility Study Inferred Resource contains 913 koz AgEq at an average grade (capped, undiluted) of 4.11 gpt Au and 295.2 gpt Ag, or 653 gpt AgEq with ETW of 0.56 metres. Comparatively, infill holes reported in this release for this vein average (uncapped, undiluted) 3.77 gpt Au and 466.65 gpt Ag, or 794 gpt AgEq with ETW of 1.10 metres.

A total of 18 new intercepts having an ETW of 0.57 metres grading 5.54 gpt Au and 680.2 gpt Ag, or 1,162 gpt AgEq have expanded the Babicanora Vista FW Vein, which is now renamed to the Babicanora Vista FW Zone in order to incorporate the presence of several new sub-parallel and semi-continuous veins between Babi Vista and Babicanora Norte veins. The Babicanora Vista FW Zone is comprised of five smaller shoots (grading >150 gpt AgEq) within an overall corridor of approximately 600 metres along strike and 150 metres across strike (see attached Figures). Additionally, the southeastern strike extension of the Babicanora Norte HW Vein has been supported by 10 vein intercepts with an ETW of 0.43 metres grading 2.00 gpt Au and 260.0 gpt Ag, or 434 gpt AgEq and a footprint (grading >150 gpt AgEq) of approximately 400 metres along strike and 100 metres high. The most significant drill hole intercepts for this release are (using ETW):

• Infill hole BV21-307; Babi Vista – 2.96 metres grading 17.13 gpt Au and 1,830.4 gpt Ag, or 3,319 gpt AgEq.
• Infill hole BV21-308; Splay – 3.55 metres grading 15.83 gpt Au and 1,439.8 gpt Ag, or 2,815 gpt AgEq.
• Expansion hole BAN21-340; Babi Vista FW Zone – 0.41 metres grading 34.40 gpt Au and 4,260.0 gpt Ag, or 7,249 gpt AgEq.

Drill intercept highlights from the infill program that are reported in this release are tabulated below. All grades are reported as uncapped and undiluted. Note that the same drill hole number may be shown for different veins. This is due to the same hole intercepting multiple veins.

All assays were completed by ALS Chemex in Hermosillo, Mexico, and North Vancouver, BC, Canada.

The drill results also include holes: BV21-290 to BV21-294, BV21-298, BV21-299, BV21-301, BV21-303 to BV21-306, BV21-310, BV21-312, BV21-314, BV21-318, BV21-320 to BV21-323 BV21-326, BV21-328, BV21-329, BV21-333, BV21-336, BV21-339 which intersected veining but were below the Company’s cutoff grade of 150 gpt AgEq.

Unnamed vein intercepts, as stated in above table, represent blind (not present at surface) veins that were intersected while drilling between or below Babi Vista, Splay, Granaditas and Babicanora Norte veins. Further drilling may show vein or zone continuity in multiple holes to suggest a new discovery.   

With the planned 2021 infill drilling nearing completion, a total of 11 drills are currently active at Las Chispas in the Babicanora Area including eight (8) surface drills and three (3) underground drills. SilverCrest’s 2021 Company-wide exploration program budget is US$42 million (see News Release dated February 24, 2021). During the first seven months of 2021, SilverCrest has incurred an estimated $14 million for the Company’s drilling programs at Las Chispas and Picacho. The focus of surface drilling efforts at Las Chispas will transition from infill to expansion and new exploration targets within the Babicanora area.  Once infill drilling is completed in Q4, 2021, the technical team will begin to evaluate the work necessary to potentially add these ounces into an updated mineral reserve and LOM in 2022.

The Qualified Person under National Instrument 43-101 Standards of Disclosure for Mineral Projects for this news release is N. Eric Fier, CPG, P.Eng, and CEO for SilverCrest, who has reviewed and approved its contents.

ABOUT
SILVERCREST METALS
 INC.
SilverCrest is a Canadian precious metals exploration and development company headquartered in Vancouver, BC, that is focused on new discoveries, value-added acquisitions and targeting production in Mexico’s historic precious metal districts. The Company’s top priority is on the high-grade, historic Las Chispas mining district in Sonora, Mexico, where it has completed a feasibility study on the Las Chispas Project and is proceeding with mine construction. Start-up of production at the Las Chispas Mine is targeted for mid-2022. SilverCrest is the first company to successfully drill-test the historic Las Chispas Property resulting in numerous high-grade precious metal discoveries. The Company is led by a proven management team in all aspects of the precious metal mining sector, including taking projects through discovery, finance, on time and on budget construction, and production.

FORWARD-LOOKING STATEMENTS


This news release contains “forward-looking statements” and “forward-looking information” (collectively “forward-looking statements”) within the meaning of applicable Canadian and United States securities legislation. These include, without limitation, statements with respect to: the strategic plans, timing and expectations for the Company’s exploration programs at the Las Chispas Project and the start up of production at the Las Chispas Mine by mid-2022. Such forward looking statements or information are based on a number of assumptions, which may prove to be incorrect. Assumptions have been made regarding, among other things: impact of the COVID-19 pandemic; the reliability of mineralization estimates, mining and development costs the conditions in general economic and financial markets; availability of skilled labour; timing and amount of expenditures related to rehabilitation and drilling programs; and effects of regulation by governmental agencies. The actual results could differ materially from those anticipated in these forward-looking statements as a result of risk factors including: uncertainty as to the impact and duration of the COVID-19 pandemic; the timing and content of work programs; results of exploration activities; the interpretation of drilling results and other geological data; receipt, maintenance and security of permits and mineral property titles; environmental and other regulatory risks; project cost overruns or unanticipated costs and expenses; and general market and industry conditions. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made. The Company undertakes no obligation to update or revise any forward-looking statements included in this news release if these beliefs, estimates and opinions or other circumstances should change, except as otherwise required by applicable law.

N. Eric Fier, CPG, P.Eng
Chief Executive Officer
SilverCrest Metals Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/silvercrest-announces-results-from-2021-infill-and-expansion-drilling-in-the-babicanora-area-301372130.html

SOURCE SilverCrest Metals Inc.

BEIJING, Sept. 9, 2021 /PRNewswire/ — Canaan Inc. (NASDAQ: CAN) (“Canaan” or the “Company”), a leading high-performance computing solutions provider, today announced that it plans to release its second quarter 2021 financial results before the market opens on Wednesday, September 15, 2021.

The Company’s management team will hold a Direct Event conference call on Wednesday, September 15, 2021, at 8:00 A.M. Eastern Time (or 8:00 P.M. Beijing Time on the same day) to discuss the financial results. Details for the conference call are as follows:

All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in numbers, the Direct Event passcode, and a unique access PIN, which can be used to join the conference call.

Investors may submit questions to the Company via [email protected] up to 24 hours before the start of the conference call. The Company’s management team will answer a selection of the submitted questions during the Q&A session of the conference call.

Additionally, a replay of the conference call will be accessible through September 22, 2021, by dialing the following numbers:

A live and archived webcast of the conference call will also be available at the Company’s investor relations website at investor.canaan-creative.com.  

About Canaan Inc.

Established in 2013, Canaan (NASDAQ: CAN), is a technology company focusing on ASIC high-performance computing chip design, chip research and development, computing equipment production, and software services. The Company’s vision is “super computing is what we do, social enrichment is why we do.” Canaan has a rich experience in chip design and streamlined production in the ASIC field. In 2013, it released and mass produced its first ASIC Bitcoin mining machine. In 2018, Canaan released the world’s first 7nm ASIC chip, providing energy efficient computing equipment to the cryptocurrency mining industry. In the same year, Canaan released the world’s first RISC-V architecture commercial edge AI chip, further harnessing the potential of ASIC technology in the field of high-performance computing and artificial intelligence.

Investor Relations Contact
Canaan Inc.
Mr. Shaoke Li
Email: [email protected]

ICR, LLC
Robin Yang
Tel: +1 (347) 396-3281
Email: [email protected]

View original content:https://www.prnewswire.com/news-releases/canaan-inc-to-report-second-quarter-2021-financial-results-on-september-15-2021-301372158.html

SOURCE Canaan Inc.

BOSTON, Sept. 9, 2021 /PRNewswire/ — Ginkgo Bioworks (“Ginkgo”), which is building the leading horizontal platform for cell programming, today announced the launch of Ayana Bio to enable a healthier future by harnessing bioactive compounds for use as complementary medicine to support human health and wellness. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (Nasdaq: SRNG), has successfully launched several new companies across a variety of end-markets, bringing together funding from strategic and financial investors. The Ferment Consortium, a company creation studio that works with Viking Global Investors and Cascade Investment, both of whom are providing capital to Ayana, was created to help ideate and launch new companies that use cell programming to support human and environmental health and well-being.

“We’ve seen that when companies launch off of the Ginkgo platform, they can spend more time developing their products and less time building the cell programming infrastructure they need to get started,” said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. “Synthetic biology has incredible potential to support human and environmental health, and we’re proud to enable innovators like Ayana Bio to launch and thrive.”

Consumers around the globe have been looking for health products that are complementary to conventional medicine to address issues ranging from overall immune and metabolic support, healthy aging and more. Many such bioactive products come from a range of natural sources such as medicinal plants and fungi. Unsustainable harvesting, variability in source organisms, and the methods of preparation all contribute to uncertainty around these important molecules and limit the potential for widespread adoption. Ginkgo’s cell programming platform will support Ayana’s mission to bring to market high purity, clean and reliable medicinal bioactives in convenient forms. Ayana is excited to start collaborating with global industry leaders in consumer packaged goods brands, supplements, specialized nutrition, OTC, and traditional medicines to bring to market standardized bioactives that provide consumers with confidence in quality and reliability. This capability positions Ayana within both the nutraceuticals and traditional medicines markets, which combined represent over $400 billion.

“Cultured products grown via fermentation of plant or microbial cells enable more resiliency, consistency, and quality of important ingredients in a range of markets,” said Jason Kakoyiannis, Head of the Ferment Consortium. “The Ayana team plans to bring this revolutionary technology to a range of notable bioactives and unlock opportunities with new products in markets that range from nutrition to herbal medicines.”

“Content standardization and reliability are some of the biggest challenges facing the agriculture-based natural product industry today,” said Effendi Leonard, Chief Technology Officer of Ayana Bio. “Biotechnology is now ready to be deployed by Ayana as a solution to deliver standardized and safe bioactive ingredients that are also made sustainably. It’s incredibly empowering to know that we have a technology platform to bring out nature’s best potential to help people stay healthy, and contribute to preserving the resources from which these amazing bioactives have been derived.”

Ayana Bio is launching with $30 million in Series A funding provided by Viking Global Investors and Cascade Investment. Ayana joins other Ginkgo Bioworks Platform Ventures such as Joyn Bio, Motif FoodWorks, Allonnia, and Verb Biotics. Motif FoodWorks recently raised a $226 million Series B round led by Ontario Teachers Pension Plan and BlackRock.

About Ayana Bio

Ayana Bio is harnessing nature’s bioactives for use as complementary medicine to support human health and wellness. Ayana collaborates with global industry leaders in consumer packaged goods brands, supplements, specialized nutrition, OTC, and herbal medicines to bring to market standardized bioactives that provide consumers with confidence in quality and reliability. Please visit www.ayanabio.com for more information.

A
bout Ginkgo Bioworks
Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company’s platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. In May 2021, Ginkgo announced a business combination with Soaring Eagle Acquisition Corp. (Nasdaq: SRNG), which, if completed, will result in Ginkgo, through a parent entity, Ginkgo Bioworks Holdings, Inc., becoming a public company. The extraordinary general meeting of Soaring Eagle’s shareholders in connection with the transaction has been scheduled for September 14, 2021 and the transaction is expected to close shortly thereafter, subject to customary closing conditions. For more information, visit www.ginkgobioworks.com.

MEDIA CONTACT:

[email protected]

INVESTOR CONTACT:


[email protected]

Additional Legal Information

Forward-Looking Statements Legend
This document contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between Ginkgo and Soaring Eagle, including statements regarding the anticipated timing of the transaction, the services offered by Ginkgo and the markets in which it operates, and Ginkgo’s projected future results. These forward-looking statements generally are identified by the words “believe,” “project,” “potential,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of Soaring Eagle’s securities, (ii) the risk that the transaction may not be completed by Soaring Eagle’s business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by Soaring Eagle, (iii) the failure to satisfy the conditions to the consummation of the transaction, including the adoption of the agreement and plan of merger by the shareholders of Soaring Eagle and Ginkgo, the satisfaction of the minimum trust account amount following redemptions by Soaring Eagle’s public shareholders and the receipt of certain governmental and regulatory approvals, (iv) the lack of a third party valuation in determining whether or not to pursue the proposed transaction, (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the agreement and plan of merger, (vi) the effect of the announcement or pendency of the transaction on Ginkgo business relationships, performance, and business generally, (vii) risks that the proposed transaction disrupts current plans of Ginkgo and potential difficulties in Ginkgo employee retention as a result of the proposed transaction, (viii) the outcome of any legal proceedings that may be instituted against Ginkgo or against Soaring Eagle related to the agreement and plan of merger or the proposed transaction, (ix) the ability to maintain the listing of Soaring Eagle’s securities on Nasdaq, (x) volatility in the price of Soaring Eagle’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo plans to operate, variations in performance across competitors, changes in laws and regulations affecting Ginkgo’s business and changes in the combined capital structure, (xi) the ability to implement business plans, forecasts, and other expectations after the completion of the proposed transaction, and identify and realize additional opportunities, and (xii) the risk of downturns in demand for products using synthetic biology. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Soaring Eagle’s proxy statement/prospectus relating to the transaction (the “Proxy Statement”), and in Soaring Eagle’s other filings with the SEC. Soaring Eagle and Ginkgo caution that the foregoing list of factors is not exclusive. Soaring Eagle and Ginkgo caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither Soaring Eagle nor Ginkgo undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Additional Information and Where to Find It
This document relates to a proposed transaction between Ginkgo and Soaring Eagle. This document does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the proposed transaction, Soaring Eagle filed a Proxy Statement on August 13, 2021. The Proxy Statement has been sent to all Soaring Eagle shareholders as of the record date of August 10, 2021. Soaring Eagle also will file other documents regarding the proposed transaction with the SEC. Before making any voting decision, investors and security holders of Soaring Eagle and Ginkgo are urged to read the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction.

Investors and security holders may obtain free copies of the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Soaring Eagle through the website maintained by the SEC at www.sec.gov. In addition, the documents filed by Soaring Eagle may be obtained free of charge by written request to Soaring Eagle at 955 Fifth Avenue, New York, NY, 10075, Attention: Eli Baker, Chief Financial Officer, (310) 209-7280.

Participants in Solicitation
Soaring Eagle and Ginkgo and their respective directors and officers may be deemed to be participants in the solicitation of proxies from Soaring Eagle’s shareholders in connection with the proposed transaction. Information about Soaring Eagle’s directors and executive officers and their ownership of Soaring Eagle’s securities is set forth in Soaring Eagle’s filings with the SEC. To the extent that holdings of Soaring Eagle’s securities have changed since the amounts printed in Soaring Eagle’s proxy statement, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the proxy statement/prospectus regarding the proposed transaction when it becomes available. You may obtain free copies of these documents as described in the preceding paragraph.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-ferment-consortium-launches-ayana-bio-to-produce-plant-and-fungal-bioactives-for-herbal-medicines-and-nutraceuticals-301372272.html

SOURCE Ginkgo Bioworks

BOSTON, Sept. 9, 2021 /PRNewswire/ — Ginkgo Bioworks (“Ginkgo”), which is building the leading horizontal platform for cell programming, today announced the launch of Verb Biotics (“Verb”), a probiotics innovation company that will identify and design new strains of probiotic bacteria with advanced properties for human nutrition, health, and wellness. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (Nasdaq: SRNG), has successfully launched several new companies across a variety of end-markets, bringing together funding from strategic and financial investors. The Ferment Consortium, a company creation studio that works with Viking Global Investors and Cascade Investment, both of whom are providing capital to Verb, was created to help ideate and launch new companies that use cell programming to support human and environmental health and well-being.

The probiotics category is a $50B global industry that’s growing rapidly. As awareness and understanding of the microbiome—the trillions of bacteria that live in the human body—has grown over the past decade, there has been tremendous interest in probiotic enhanced foods, beverages and supplement products as part of lifestyle regimens that reduce chronic disease and improve wellness. These products have used strains of bacteria common to yogurt and other fermented products. However, there are a number of product development challenges involved, including limited shelf life and stability, and the need to identify strains with more specific metabolic profiles.

“The probiotics industry has been in an era of partial understanding that has struggled with a need for more mechanistic understanding of how probiotics impact health,” said Mike Bush, Verb advisor and Executive Board Member of the International Probiotics Association. “Ginkgo has a suite of robust tools that will enable this new company to transform the paradigm for probiotics in the supplement and food markets.”

“Verb will be using microbes as a way to deliver beneficial molecules into the gut or to ‘bio-transform’ food substrates into substances our body needs. People are not getting what they can from their food and, for a variety of reasons, we absorb a fraction of the available nutrients in our diet,” said Todd Beckman, Verb advisor and former founder of probiotic company Goodbelly Probiotics.  “Gut microbiome science repeatedly points to the population of microbes in the gut as a major actor in many aspects of wellness, from actual ability to extract nutrients, to secreting neurotransmitters that affect mood, satiety/obesity, immune system function and more.”

Ginkgo has significant expertise in the discovery and design of microbes for a wide array of functions. Verb Biotics plans to leverage Ginkgo’s high-throughput platform to perform sequencing, proteomics and metabolomics analysis, pathway design, cell culturing, and fermentation to improve the design and development of probiotics. Verb joins other Ginkgo Bioworks Platform Ventures such as Joyn Bio, Motif FoodWorks, Allonnia, and Ayana Bio. Motif FoodWorks recently raised a $226 million Series B round led by Ontario Teachers Pension Plan and BlackRock.

“We are really happy to be able to build on our microbial codebase and add to our deep capabilities that will help nutrition and food players diversify their probiotic solutions across the consumer space,” said Jason Kelly, CEO of Ginkgo. “Together, we hope Ginkgo and Verb can unlock the benefits of gut microbes with precision and specificity to truly deliver on the promise of microbes for human health.”

Verb is launching with $30 million in Series A funding provided by Viking Global Investors and Cascade Investment.

About Ginkgo Bioworks
Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company’s platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. In May 2021, Ginkgo announced a business combination with Soaring Eagle Acquisition Corp. (Nasdaq: SRNG), which, if completed, will result in Ginkgo, through a parent entity, Ginkgo Bioworks Holdings, Inc., becoming a public company. The extraordinary general meeting of Soaring Eagle’s shareholders in connection with the transaction has been scheduled for September 14, 2021 and the transaction is expected to close shortly thereafter, subject to customary closing conditions. For more information, visit www.ginkgobioworks.com.

About Verb Biotics
Verb is a probiotics innovation company that identifies and designs new probiotic bacteria with advanced properties for human nutrition, health, and wellness. We use Ginkgo Bioworks‘ cell engineering platform with the goal of improving overall human health through probiotics technology that provides consumers a positive “I feel the effect” experience. Please visit www.verbbiotics.com for more information.

MEDIA CONTACT:

[email protected]

INVESTOR CONTACT:


[email protected]

Additional Legal Information

Forward-Looking Statements Legend
This document contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between Ginkgo and Soaring Eagle, including statements regarding the anticipated timing of the transaction, the services offered by Ginkgo and the markets in which it operates, and Ginkgo’s projected future results. These forward-looking statements generally are identified by the words “believe,” “project,” “potential,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of Soaring Eagle’s securities, (ii) the risk that the transaction may not be completed by Soaring Eagle’s business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by Soaring Eagle, (iii) the failure to satisfy the conditions to the consummation of the transaction, including the adoption of the agreement and plan of merger by the shareholders of Soaring Eagle and Ginkgo, the satisfaction of the minimum trust account amount following redemptions by Soaring Eagle’s public shareholders and the receipt of certain governmental and regulatory approvals, (iv) the lack of a third party valuation in determining whether or not to pursue the proposed transaction, (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the agreement and plan of merger, (vi) the effect of the announcement or pendency of the transaction on Ginkgo business relationships, performance, and business generally, (vii) risks that the proposed transaction disrupts current plans of Ginkgo and potential difficulties in Ginkgo employee retention as a result of the proposed transaction, (viii) the outcome of any legal proceedings that may be instituted against Ginkgo or against Soaring Eagle related to the agreement and plan of merger or the proposed transaction, (ix) the ability to maintain the listing of Soaring Eagle’s securities on Nasdaq, (x) volatility in the price of Soaring Eagle’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo plans to operate, variations in performance across competitors, changes in laws and regulations affecting Ginkgo’s business and changes in the combined capital structure, (xi) the ability to implement business plans, forecasts, and other expectations after the completion of the proposed transaction, and identify and realize additional opportunities, and (xii) the risk of downturns in demand for products using synthetic biology. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Soaring Eagle’s proxy statement/prospectus relating to the transaction (the “Proxy Statement”), and in Soaring Eagle’s other filings with the SEC. Soaring Eagle and Ginkgo caution that the foregoing list of factors is not exclusive. Soaring Eagle and Ginkgo caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither Soaring Eagle nor Ginkgo undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Additional Information and Where to Find It
This document relates to a proposed transaction between Ginkgo and Soaring Eagle. This document does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the proposed transaction, Soaring Eagle filed a Proxy Statement on August 13, 2021. The Proxy Statement has been sent to all Soaring Eagle shareholders as of the record date of August 10, 2021. Soaring Eagle also will file other documents regarding the proposed transaction with the SEC. Before making any voting decision, investors and security holders of Soaring Eagle and Ginkgo are urged to read the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction.

Investors and security holders may obtain free copies of the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Soaring Eagle through the website maintained by the SEC at www.sec.gov. In addition, the documents filed by Soaring Eagle may be obtained free of charge by written request to Soaring Eagle at 955 Fifth Avenue, New York, NY, 10075, Attention: Eli Baker, Chief Financial Officer, (310) 209-7280.

Participants in Solicitation
Soaring Eagle and Ginkgo and their respective directors and officers may be deemed to be participants in the solicitation of proxies from Soaring Eagle’s shareholders in connection with the proposed transaction. Information about Soaring Eagle’s directors and executive officers and their ownership of Soaring Eagle’s securities is set forth in Soaring Eagle’s filings with the SEC. To the extent that holdings of Soaring Eagle’s securities have changed since the amounts printed in Soaring Eagle’s proxy statement, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the proxy statement/prospectus regarding the proposed transaction when it becomes available. You may obtain free copies of these documents as described in the preceding paragraph.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-ferment-consortium-launches-verb-biotics-a-probiotics-innovation-company-to-address-market-demands-for-effective-probiotics-301372266.html

SOURCE Ginkgo Bioworks

GUELPH, ON, Sept.  9, 2021 /PRNewswire/ — Canadian Solar Inc. (“Canadian Solar” or “the Company”) (NASDAQ: CSIQ) today announced that its majority-owned subsidiary, CSI Solar Co., Ltd. (“CSI Solar”) has closed a 350 MW / 1400 MWh contract to provide the fully-integrated battery storage system, EPC (engineering, procurement and construction) and long term maintenance service to the Crimson stand-alone battery storage project in Riverside County, California.

The Crimson storage project is 80% owned by Axium Infrastructure (“Axium”) and 20% owned by Recurrent Energy, Canadian Solar’s wholly-owned subsidiary. Crimson holds two approximately 15-year stand-alone storage contracts with local utilities Southern California Edison (“SCE”) and Pacific Gas and Electric (“PG&E”), which are part of the California Public Utilities Commission’s (“CPUC”) reliability procurements.

CSI Solar will provide the fully-integrated battery solution, EPC and long-term operation services for the Crimson storage project. The integrated solution includes a fully bankable, lithium iron phosphate-based technology battery system. Equipment delivery and construction is expected to start soon and the project is expected to reach commercial operation by the summer of 2022. In addition, CSI Solar will support the battery storage system with 15-year service agreements as well as capacity and performance guarantees, ensuring system output, safety and reliability. The long term service agreement includes the operation and maintenance of the battery systems as well as their future augmentation services. The project will be augmented with planned additional installed battery capacity of approximately 300 MWh to be installed on regular frequencies over the 15-year term of the long term service contract.

“The Crimson storage project will help improve California’s grid reliability and safety by providing critically-needed resource adequacy capacity. It will also support California’s efforts to decarbonize its economy while creating jobs and fight climate change,” said Dr. Shawn Qu, Chairman and CEO of Canadian Solar. “We are proud that Canadian Solar is not only developing the stand-alone Crimson storage project through Recurrent Energy, but also providing the technological solution and long term service agreement through CSI Solar, now also delivering full turnkey EPC battery solutions. We thank our partner Axium for their trust and support and look forward to further collaborating and executing on this massive project over the coming quarters.”

About Canadian Solar Inc.
Canadian Solar was founded in 2001 in Canada and is one of the world’s largest solar technology and renewable energy companies. It is a leading manufacturer of solar photovoltaic modules, provider of solar energy and battery storage solutions, and developer of utility-scale solar power and battery storage projects with a geographically diversified pipeline in various stages of development. Over the past 20 years, Canadian Solar has successfully delivered over 59 GW of premium-quality, solar photovoltaic modules to customers across the world. Likewise, since entering the project development business in 2010, Canadian Solar has developed, built and connected over 6.1 GWp in over 20 countries across the world. Currently, the Company has around 400 MWp of projects in operation, nearly 6 GWp of projects under construction or in backlog (late-stage), and an additional 16 GWp of projects in pipeline (mid- to early- stage). Canadian Solar is one of the most bankable companies in the solar and renewable energy industry, having been publicly listed on the NASDAQ since 2006. For additional information about the Company, follow Canadian Solar on LinkedIn or visit www.canadiansolar.com.

Safe Harbor/Forward-Looking Statements 
Certain statements in this press release, including but not limited to the use of proceeds, are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially. These statements are made under the “Safe Harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by such terms as “believes,” “expects,” “anticipates,” “intends,” “estimates,” the negative of these terms, or other comparable terminology. Factors that could cause actual results to differ include general business and economic conditions and the state of the solar industry; volatility, uncertainty, delays and disruptions related to the COVID-19 pandemic; governmental support for the deployment of solar power; future available supplies of high-purity silicon; demand for end-use products by consumers and inventory levels of such products in the supply chain; changes in demand from significant customers; changes in demand from major markets such as Japan, the U.S., India, China and Brazil; changes in customer order patterns; changes in product mix; capacity utilization; level of competition; pricing pressure and declines in average selling prices; delays in new product introduction; delays in utility-scale project approval process; delays in utility-scale project construction; delays in the completion of project sales; delays in the process of qualifying to list the CSI Solar subsidiary in the PRC; continued success in technological innovations and delivery of products with the features customers demand; shortage in supply of materials or capacity requirements; availability of financing; exchange rate fluctuations; litigation and other risks as described in the Company’s SEC filings, including its annual report on Form 20-F filed on April 19, 2021. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, level of activity, performance, or achievements. Investors should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and Canadian Solar undertakes no duty to update such information, except as required under applicable law.

View original content:https://www.prnewswire.com/news-releases/canadian-solars-csi-solar-to-provide-the-fully-integrated-battery-storage-system-epc-and-long-term-services-to-the-1-4-gwh-crimson-project-301372203.html

SOURCE Canadian Solar Inc.

CHICAGO and NEW YORK, Sept. 9, 2021 /PRNewswire/ — Donnelley Financial Solutions (NYSE: DFIN), a leading risk and compliance company today announced a strategic partnership with Diligent Corporation, the global leader in SaaS governance, to equip organizations with the financial and governance tools that help them scale with confidence, from the early stages of business through to a traditional IPO or SPAC.

The partnership provides organizations with a powerful end-to-end solution that addresses many of the regulatory and governance challenges companies face on the road to an IPO: establishing a board structure, financial reporting, D&O and SEC filing, and ensuring SOX compliance. With DFIN bringing its world-class financial reporting and SEC filing capabilities and Diligent bringing its expertise in governance and board leadership, this solution will help companies get ready for the realities of being listed on the public market and address the complexities of a public offering.

“DFIN’s IPO leadership is founded not just on experience and service, but, on technology. Combined with our expertise, together we will better align companies’ governance and financial practices with investor expectations,” said Brian Stafford, CEO of Diligent. “We are seeing unprecedented momentum in the market from companies looking to prepare for an IPO, seeking solutions that help them get board ready, prepare for SOX compliance and ensure disclosure readiness. Partnering with DFIN and leveraging their financial and regulatory expertise will help our clients develop the systems they’ll need for the future, while ensuring that compliance requirements are met.”

“Working with Diligent to deliver a purpose-built, cost-effective solution that focuses on mitigating compliance risks before IPO, enables us to provide greater value for our clients,” said Craig Clay, president of Global Capital Markets at DFIN. “Our common focus around the importance of prioritizing compliance through best of breed technology, especially on the path to IPO, strengthens our combined solution and empowers our clients to scale with confidence. Together, we will continue to work to help leaders and executives establish good governance practices from the seed stage through exit and beyond.”

Learn more about the partnership by registering for DFIN and Diligent’s upcoming webinar, “The IPO Journey: Good Governance Today, IPO Tomorrow.” The webinar will take place on October 7 at 12 pm EDT.

About Diligent Corporation
Diligent is a leading governance, risk, and compliance (GRC) SaaS company, serving more than one million users from over 25,000 organizations around the globe. Our modern GRC platform ensures boards, executives and other leaders have a holistic, integrated view of audit, risk, information security, ethics, and compliance across the organization. Diligent brings technology, insights, and confidence to leaders so they can build more effective, equitable and successful organizations.

About Donnelley Financial Solutions (DFIN)
DFIN is a leading global risk and compliance solutions company. We provide domain expertise, enterprise software and data analytics for every stage of our clients’ business and investment lifecycles. Markets fluctuate, regulations evolve, technology advances, and through it all, DFIN delivers confidence with the right solutions in moments that matter. Learn about DFIN’s end-to-end risk and compliance solutions online at DFINsolutions.com or you can also follow us on Twitter @DFINSolutions or on LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/dfin-partners-with-diligent-on-new-pre-ipo-solution-helping-companies-establish-modern-governance-audit-and-compliance-practices-ahead-of-public-offerings-301372151.html

SOURCE Donnelley Financial Solutions